Clinical Study
Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA
Table 2
Distribution of estimated peak concentrations (
) for isoniazid and rifampin.
| | Drug | Diabetics (early TDM) | Nondiabetic slow responders (standard TDM) | value |
| | Rifampin (expected range 8–24 g/mL) | | | | | Mean g/mL ± SD | | | | | Below expected range (%N) | 12 (60) | 4 (41) | |
| | Isoniazid (daily) (expected range 3–6 g/mL) | | | | | Mean g/mL ± SD | | | | | Below expected range (%N) | 11 (65) | 5 (63) | |
| | Isoniazid (intermittent) (expected range 9–18 g/mL) | | | | | Mean g/mL ± SD | | | | | Below expected range (%N) | 3 (75) | 1 (17) | |
|
|
TDM: therapeutic drug monitoring (see Figure 1).
|
